2024-03-18 16:00Financial Performance - The company's revenue for 2023 reached approximately ¥40.34 billion, representing a 2.51% increase compared to ¥39.35 billion in 2022[20]. - Net profit attributable to shareholders for 2023 was approximately ¥9.61 billion, a 9.00% increase from ¥8.81 billion in 2022[20]. - The net profit after deducting non-recurring gains and losses was approximately ¥9.75 billion, reflecting a 16.81% increase from ¥8.34 billion in 2022[20]. - The net cash flow from operating activities for 2023 was approximately ¥13.39 billion, an increase of 26.10% compared to ¥10.62 billion in 2022[20]. - The total assets at the end of 2023 were approximately ¥73.67 billion, a 13.88% increase from ¥64.69 billion at the end of 2022[20]. - The net assets attributable to shareholders at the end of 2023 were approximately ¥55.12 billion, an 18.31% increase from ¥46.59 billion at the end of 2022[20]. - Basic earnings per share for 2023 were ¥3.27, an increase of 8.64% from ¥3.01 in 2022[21]. - The diluted earnings per share for 2023 were ¥3.24, reflecting a 14.89% increase from ¥2.82 in 2022[21]. - The weighted average return on net assets for 2023 was 18.99%, a decrease of 1.63 percentage points from 20.62% in 2022[21]. - The company achieved operating revenue of RMB 40,340,806,877.04, a year-on-year increase of 2.51%[44]. - Gross profit reached RMB 1,661,200,720, representing a 13.18% increase compared to the same period last year, with a gross margin of 41.17%, up 3.88 percentage points[45]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of RMB 9.8336 per 10 shares, totaling RMB 2,882,031,329.68 (including tax) to shareholders[4]. - The cash dividend represents 30% of the net profit attributable to ordinary shareholders in the consolidated financial statements, which is RMB 9,606,749,135.07[142]. - The company has established a profit distribution policy ensuring that cash dividends in any three consecutive years will not be less than 30% of the average distributable profit for those years[140]. - The company is committed to a sustainable profit distribution mechanism that considers strategic development goals, shareholder interests, and cash flow conditions[140]. Business Operations and Strategy - The company plans to continue expanding its market presence and investing in new product development and technologies[19]. - The company is focusing on enhancing global business synergies and accelerating its globalization efforts[45]. - The company aims to enhance its service capabilities and expand its business scale globally, focusing on integrated new drug R&D and production services[78]. - The company plans to strengthen its digital transformation and improve data utilization to enhance operational efficiency[81]. - The company will continue to invest in cutting-edge technologies, including peptide drugs, oligonucleotide drugs, and targeted protein degradation technology (PROTAC)[81]. - The company is focused on developing and selecting talent suitable for various business scenarios to enhance the quality of its management team[139]. Client and Market Engagement - The company added over 1,200 new clients in 2023, with active clients exceeding 6,000, indicating a strong demand for services globally[30]. - Revenue from U.S. clients amounted to CNY 26.13 billion, a year-on-year increase of 42% when excluding specific commercial production projects[30]. - Revenue from the top 20 global pharmaceutical companies reached CNY 16.11 billion, with a year-on-year growth of 44% when excluding specific commercial production projects[30]. - The company’s revenue from existing clients accounted for 98% of total revenue, amounting to CNY 39.63 billion, which is a 30% increase when excluding specific commercial production projects[30]. Risks and Challenges - The company faces risks related to a potential decline in demand for pharmaceutical research services, which could negatively impact business if industry trends slow or outsourcing ratios decrease[83]. - Regulatory changes in the pharmaceutical research services industry pose a risk, as the company must adapt to evolving policies and regulations in various countries[84]. - Increased competition in the global pharmaceutical research services market may threaten the company's market position if it fails to enhance its research and commercial advantages[85]. - Global operations expose the company to risks from international policy changes, geopolitical tensions, and unforeseen events that could disrupt business continuity[87]. - Currency exchange rate fluctuations, particularly a significant appreciation of the RMB, could lead to increased costs and reduced order volumes[90]. Governance and Compliance - The company has established a complete and independent governance structure, ensuring independence in assets, personnel, finance, organization, and business from the actual controller[95]. - The company has implemented measures to prevent the actual controller and related parties from occupying company funds, ensuring financial independence[96]. - The company has a robust internal management and control system to safeguard shareholder rights and ensure stable development[94]. - The company has not engaged in any related party transactions that would compromise its independence[96]. - The company reported no penalties from securities regulatory agencies in the past three years[121]. Environmental Responsibility - The company invested 14.6138 million yuan in environmental protection during the reporting period[151]. - The company has established a mechanism for environmental protection and is compliant with relevant regulations[151]. - The company’s wastewater treatment facilities across various locations are operating normally and effectively managing waste, ensuring compliance with environmental standards[196]. - The company has implemented a waste management program to oversee the generation, collection, classification, and disposal of industrial solid waste and hazardous waste[165]. - The company’s noise levels at the project boundary meet the Class 2 standards of the Industrial Enterprise Boundary Environmental Noise Emission Standards[165].